Literature DB >> 17989878

Effects of tetrandrine on apoptosis and radiosensitivity of nasopharyngeal carcinoma cell line CNE.

Xinchen Sun1, Ruizhi Xu, Yuxia Deng, Hongyan Cheng, Jun Ma, Jiazhong Ji, Yingfeng Zhou.   

Abstract

Tetrandrine is known to exert antitumor effect, however, little is known about its effect on nasopharyngeal carcinoma cells. In this study, we tested tetrandrine-induced apoptosis and radiosensitivity in nasopharyngeal carcinoma cell line CNE and investigated the possible mechanisms. Using flow cytometry and DNA electrophoresis, we found that tetrandrine could induce cell apoptosis. Further, it was shown that the level of Bcl-2 mRNA decreased and Bax mRNA increased after addition of tetrandrine by using reverse transcription-polymerase chain reaction. X-ray-induced G2 arrest was abrogated by treatment with tetrandrine, as detected by flow cytometry and mitotic index. The accumulation of cyclinB1 protein and the suppression of Cdc2 tyrosine-15 and Cdc25C serine-216 phosphorylation were detected in irradiated cells treated with tetrandrine using Western blot analysis. Taken together, these results show that tetrandrine can induce apoptosis and abrogate radiation-induced G2 arrest in CNE cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17989878     DOI: 10.1111/j.1745-7270.2007.00349.x

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  13 in total

1.  Tetrandrine enhances radiosensitivity through the CDC25C/CDK1/cyclin B1 pathway in nasopharyngeal carcinoma cells.

Authors:  Jun Wang; Lihong Chang; Xiaoping Lai; Xia Li; Zhiyuan Wang; Zizhen Huang; Jiancong Huang; Gehua Zhang
Journal:  Cell Cycle       Date:  2018       Impact factor: 4.534

2.  Fangchinoline induces autophagic cell death via p53/sestrin2/AMPK signalling in human hepatocellular carcinoma cells.

Authors:  Ning Wang; Weidong Pan; Meifen Zhu; Maosheng Zhang; Xiaojian Hao; Guangyi Liang; Yibin Feng
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

3.  Fangchinoline suppresses the growth and invasion of human glioblastoma cells by inhibiting the kinase activity of Akt and Akt-mediated signaling cascades.

Authors:  Bingyu Guo; Peng Xie; Jingyuan Su; Tingting Zhang; Xiaoming Li; Guobiao Liang
Journal:  Tumour Biol       Date:  2015-09-25

4.  Fangchinoline targets PI3K and suppresses PI3K/AKT signaling pathway in SGC7901 cells.

Authors:  Feng Tian; Ding Ding; Dandan Li
Journal:  Int J Oncol       Date:  2015-04-09       Impact factor: 5.650

5.  Anticancer Activity of Tetrandrine by Inducing Apoptosis in Human Breast Cancer Cell Line MDA-MB-231 In Vivo.

Authors:  Chun-Hui Wang; Jia-Min Yang; Yu-Bo Guo; Jing Shen; Xiao-Hua Pei
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-30       Impact factor: 2.629

6.  Alkaloids isolated from natural herbs as the anticancer agents.

Authors:  Jin-Jian Lu; Jiao-Lin Bao; Xiu-Ping Chen; Min Huang; Yi-Tao Wang
Journal:  Evid Based Complement Alternat Med       Date:  2012-09-04       Impact factor: 2.629

7.  Tetrandrine blocks autophagic flux and induces apoptosis via energetic impairment in cancer cells.

Authors:  W Qiu; M Su; F Xie; J Ai; Y Ren; J Zhang; R Guan; W He; Y Gong; Y Guo
Journal:  Cell Death Dis       Date:  2014-03-13       Impact factor: 8.469

Review 8.  Tetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapy.

Authors:  Ting Liu; Xin Liu; Wenhua Li
Journal:  Oncotarget       Date:  2016-06-28

9.  Tetrandrine Exerts a Radiosensitization Effect on Human Glioma through Inhibiting Proliferation by Attenuating ERK Phosphorylation.

Authors:  Ji-Wei Ma; Yong Zhang; Ji-Cheng Ye; Ru Li; Yu-Lin Wen; Jian-Xian Huang; Xue-Yun Zhong
Journal:  Biomol Ther (Seoul)       Date:  2017-03-01       Impact factor: 4.634

Review 10.  Natural products: a hope for glioblastoma patients.

Authors:  Raghupathy Vengoji; Muzafar A Macha; Surinder K Batra; Nicole A Shonka
Journal:  Oncotarget       Date:  2018-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.